Federal Register / Vol. 65, No. 74 / Monday, April 17, 2000 / Notices 20471

technology, as outlined in the CRADA

Collaborator’s proposal.

6. The demonstration of expertise in

the commercial development and

production of products related to this

area of technology.

7. The level of financial support the

CRADA Collaborator will provide for

CRADA-related Government activities.

8. The willingness to cooperate with

the National Cancer Institute in the

timely publication of research results.

9. The agreement to be bound by the

appropriate DHHS regulations relating

to human subjects and to all PHS

policies relating to the use and care of

laboratory animals.

10. The willingness to accept the legal

provisions and language of the CRADA

with appropriate modifications

pertaining to the software-based

technology sought to be developed.

These provisions govern the distribution

of future patent rights to CRADA

inventions. Generally, the rights of

ownership are retained by the

organization that is the employer of the

inventor with (1) the grant of a license

for research and other Government

purposes to the Government when the

CRADA Collaborator’s employee is the

sole inventor, or (2) the grant of an

option to elect an exclusive or

nonexclusive license to the CRADA

Collaborator when the Government

employee is the sole inventor.

Dated: April 6, 2000.

Kathleen Sybert,

Chief, Technology Development and

Commercialization Branch, National Cancer

Institute, National Institutes of Health.

[FR Doc. 00–9429 Filed 4–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. Government and

are available for licensing in the U.S. in

accordance with 35 U.S.C. 207 to

achieve expeditious commercialization

of results of federally-funded research

and development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by

contacting John Rembosek, Ph.D., at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7056 ext. 270; fax: 301/402–0220;

e-mail: jr312d@nih.gov. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Methods and Compositions for

Correlating CCR5 Expression With

Essential Hypertension

Dr. Thomas O’Brien (NCI)

DHHS Reference Number E–257–99/0

filed October 14, 1999

Hypertension is a disease which

afflicts as many as 1 in 5 persons in the

United States and is the most common

cause of visits to physicians. Once

diagnosed with hypertension, treatment

of the disease is lifelong. There is

mounting evidence that lifestyle

changes can prevent the usual rise in

blood pressure with age, but for patients

whose hypertension cannot be

adequately treated by lifestyle changes,

drug therapy must be instigated which

can be difficult to control and have

adverse side affects.

The present invention mutation in the

CC-chemokine receptor 5 (CCR5) gene

and an increased risk of developing

hypertension. This technology will

allow for the screening of individuals

for the presence of the CCR5–D32/D32

genotype which correlates with an

increased risk of developing

hypertension and possibly prevent its

occurrence through adequate

antihypertensive therapy.

This technology may lead to a method

of treating or preventing hypertension

through the administration of: (1) an

effective amount of a CCR5 expression

enhancing agent; (2) CCR5 activity

enhancing agent; (3) an effective amount

of CCR5; or (4) an effective amount of

a nucleic acid encoding CCR5. Also, this

technology can be employed as a

method of identifying an agent that

could be used to treat or prevent

hypertension through the above

identified processes.

Cloning of the Human Nuclear Receptor

Co-Repressor Gene

Johnson M. Liu, Jianxiang Wang

(NHLBI)

DHHS Reference No. E–088—99/0 filed

August 3, 1999

Alteration in the expression of human

genes is critical to the development and

progression of many diseases. These

include, among others, cancer,

inflammation, cardiovascular disease,

hypercholesterolemia, high blood

pressure, and diabetes. The Human

Nuclear Receptor Co-Repressor (HuNCor) gene represents a technology that

may be used to alter the transcription of

genes. It provides a general mechanism

by which many genes may be

modulated throughout the entire range

of being turned on to being completely

turned off. The Hun-Cor gene is a

ubiquitously expressed gene that codes

for a protein that silences other genes.

It does this by recruiting an enzyme

complex that causes local folding of

chromatin, not allowing other

transcription factors to work. Hun-Cor

represents a powerful research tool that

can be used to study gene expression

and characterization for many different

genes. It may also be useful as a target

for the isolation of pharmaceutical

compounds that enhance or inhibit

expression of genes.

Dated: April 7, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 00–9430 Filed 4–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by

contacting Uri Reichman, at the Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7736 ext. 240; fax: 301/402–0220;

e-mail: ur7A@nih.gov. A signed

Confidential Disclosure Agreement will